sapacitabine

Sapacitabine (CS682) 是一种可口服的核苷类似物前体化合物，具有潜在的抗肿瘤活性，可用于研究急性髓系白血病。

CNDAC hydrochloride 是一种核苷类似物，是沙帕他滨的代谢物。

RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.

CNDAC, a nucleoside analog, is a major metabolite of oral drug sapacitabine.